DR. ELAZAR RABBANI, Chairman of the Board of Directors, Secretary, and Chief Executive Officer, Enzo Biochem’s founder, has served as Chairman and CEO of the Company since its inception in 1976. Dr. Rabbani has authored numerous scientific publications in the field of molecular biology, in particular, nucleic acid labeling and detection. He is also the lead inventor of many of the Company's pioneering patents covering a wide range of technologies and products. Dr. Rabbani received his Bachelor of Arts degree from New York University in Chemistry and his Ph.D. in Biochemistry from Columbia University. He is a member of the American Society for Microbiology.

BARRY W. WEINER President, Treasurer, Chief Financial Officer and Director, is a founder of Enzo Biochem, Inc. He has served as the Company's President since 1996, and previously held the position of Executive Vice President. Before his employment with Enzo, he worked in several managerial and marketing positions at the Colgate Palmolive Company. Mr. Weiner is a Director of the New York Biotechnology Association. He received his Bachelor of Arts degree in Economics from New York University and a Master of Business Administration in Finance from Boston University.

DR. CARL W. BALEZENTIS President, Enzo Life Sciences, Inc. has held this position since 2006. Before his employment with Enzo, he was CEO of Lark Technologies, Inc. from 2000 to 2004, prior to its acquisition by Genaissance Pharmaceuticals, Inc. Subsequent to the acquisition he held the positions of President of Lark Technologies, Inc., and Senior Vice President of Genaissance. From 1998 to 2000 he has held numerous executive positions in the life sciences industry at Sigma-Aldrich, Perceptive Scientific Instruments, Inc., Applied Biosystems, Inc. (now Applera) and Promega Corporation. Dr. Balezentis holds a Ph.D. in Genetics from the University of Arizona and completed a Post Doctoral Fellowship at M.D. Anderson Cancer Center in Houston, TX.

Dr. Christine T. Fischette President, Enzo Therapeutics, Inc. has held this position since January 2008. Before her employment with Enzo, she was Executive Director and Head of Negotiation, Global Business Development and Licensing for various therapeutic Business Franchise Boards at Novartis Pharmaceuticals, a division of Novartis Ag from 1999-2007. She held various positions of increasing responsibility at Pfizer Pharmaceuticals, NY and directed preclinical/clinical development, medical marketing, and was head of Pfizer’s US commercial arm for diabetes before joining business development and licensing from 1987-1999. Prior to her work experience at Pfizer, she conducted research as Senior Scientist at Hoffmann-La Roche, Inc. and as a Post-Doctoral Fellow at Rockefeller University. Dr. Fischette holds a Ph.D. in Physiology from the University of Medicine & Dentistry of New Jersey and a B.A. in Biology Education from Rutgers University (1973).

ANDREW R. CRESCENZO, CPA Senior Vice President of Finance for the Company has held this position since 2006. Before joining the Company, Mr. Crescenzo was an Executive Director from 2002 to 2006 and a Senior Manager from 1997 to 2003 at Grant Thornton LLP. From 1993 to 1997 he served as Vice President and Chief Financial Officer of J. D’Addario & Co, Inc and was employed at Ernst and Young LLP from 1984 to 1993. Mr. Crescenzo is a Certified Public Accountant and received his Bachelors of Business Administration from Adelphi University.

DAVID C. GOLDBERG Vice President of Corporate Development for Enzo Biochem and Senior Vice President of Enzo Clinical Labs has been employed with the Company since 1985. He has held several managerial positions within Enzo Biochem. Mr. Goldberg also held management and marketing positions with DuPont-NEN and Gallard Schlesinger Industries before joining the Company. He received a Master of Science degree in Microbiology from Rutgers University and a Master of Business Administration in Finance from New York University.

Andrew Whiteley, Chief Operating Officer, Enzo Life Sciences and Vice President of Business Development of Enzo Biochem, has been employed with the company since May 2008. Previously, Mr. Whiteley held the position of CEO at Vitra Biosciences (2003 to 2005) and CEO of InforMax from 2002 to 2003. Prior to that Mr. Whiteley held various positions at Amersham Pharmacia Biotech (now part of GE Healthcare) including VP Bioinformatics and VP Sequencing Business. Mr.Whiteley graduated from Nottingham University, England with a joint honors degree in Biochemistry and Chemistry.

KEVIN KRENITSKY MD President, Enzo Clinical Labs, Inc, has been employed at Enzo since March 2009 .Prior to joining Enzo Clinical Labs, Dr. Krenitsky was Chief Executive Officer of Bioserve Biotechnologies Ltd, a global biotech company that validates, processes, and develops molecular diagnostics. Prior to Bioserve, he was Chief Executive Officer of Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. He previously served as Senior Vice President and Division Head at SeraCare Life Sciences’ Genomics Collaborative Division (GCI), where he managed all worldwide diagnostic and pharmaceutical R&D collaborations. Dr Krenitsky earned an MD degree fro Jefferson Medical College in Philadelphia, PA.

HERBERT B. BASS Vice President of Finance for the Company and is also Senior Vice President of Enzo Clinical Labs. Before his promotion in 1989 to Vice President of Finance, Mr. Bass served as the Corporate Controller of the Company. Mr. Bass has been with the Company since 1986. From 1977 to 1986, Mr. Bass held various positions at Danziger and Friedman, Certified Public Accountants, the latest of which was audit manager. Mr. Bass received a Bachelor of Business Administration degree in Accounting from Bernard M. Baruch College.

Natalie Bogdanos, Esq. General and Patent Counsel, has been employed at Enzo since 2003. Ms. Bogdanos is admitted in New York State; U.S. District Court, Southern and Eastern Districts of New York; and the U.S. Court of Appeals, Federal Circuit.. Prior to working at Enzo, Ms. Bogdanos was employed at Amster, Rothstein & Ebenstein. Ms. Bogdanos received her Juris Doctorate from New York Law School and her Bachelor's Degree in Biology from Queens College of the City University of New York. She is registered to practice in the United States Patent & Trademark Office. Prior to attaining her law degree, Ms. Bogdanos engaged in molecular biology research for several years at the Public Health Research Institute and authored scientific publications regarding the same.

Ronald C. Fedus, Esq. Patent Counsel, has been with Enzo since 1990. He is admitted in New York State. Before this, Mr. Fedus worked at the law office of Darby and Darby, LLC. He is a member of the Patent Bar and has served on the Association of the Bar of the City of New York. He holds a Juris Doctorate from Northeastern School of Law and a Master of Science degree in Biochemistry and Molecular Biology from Northeastern University.

BERNARD KASTEN, MD has been a director since January 2008. Dr. Kasten has been serving as Chairman of the Board of Cleveland Biolabs since August 2006. From 1995 to 2004, Dr. Kasten served at Quest Diagnostics Incorporated where he was Chief Laboratory Officer and most recently Vice President of Medical Affairs of its MedPlus Inc. subsidiary. Dr. Kasten served as a director of SIGA Technologies from May 2003 to December 2006, and as SIGA’s Chief Executive Officer from July 2004 through April 2006. Dr. Kasten currently serves as a director of GeneLink Inc. and SeraCare Life Sciences Inc. Dr. Kasten is also a director of several privately held companies. Dr. Kasten is a graduate of the Ohio State University College of Medicine. His residency was served at the University of Miami, Florida and he was awarded fellowships at the National Institutes of Health Clinical Center and NCI, Bethesda, Maryland. He is a diplomat of the Board of Pathology with certification in anatomic and clinical pathology with sub-specialty certification in Medical Microbiology.

IRWIN C. GERSON has been a Director of the Company since May 2001, and is Chairman of the Compensation Committee. From 1995 until December 1998, Mr. Gerson served as Chairman of Lowe McAdams Healthcare and prior thereto had been, since 1986, Chairman and Chief Executive Officer of William Douglas McAdams, Inc., one of the largest advertising agencies in the U.S. specializing in pharmaceutical marketing and communications to healthcare professionals. In February 2000, he was inducted into the Medical Advertising Hall of Fame. He was a director of Andrx Corporation, a NASDAQ listed company which specializes in proprietary drug delivery technologies until November 2006. From 1990-1999, he was Chairman of the Council of Overseers of the Arnold and Marie Schwartz College of Pharmacy and has served as a trustee of The Albany College of Pharmacy and Long Island University. He was elected President of the Advisory Board of Florida Atlantic University Lifelong Learning Society in October 2006. Mr. Gerson has a Bachelor of Science in Pharmacy from Fordham University and an MBA from the NYU Graduate School of Business Administration.

MELVIN F. LAZAR, CPA has been a Director of the Company since August 2002, the Lead Independent Director since October 2005, and is Chairman of the Audit Committee. Mr. Lazar was a founding partner of the public accounting firm of Lazar, Levine & Felix LLP from 1969 until October 2002. Mr. Lazar is a board member and chairman of the audit committee of Arbor Realty Trust, Inc. (ABR: NYSE). Arbor is a real estate investment trust (REIT) formed to invest in real estate related bridge and mezzanine loans, preferred equity investments and other real estate related assets. Mr. Lazar is a board member and serves as the Chairman of the Audit Committee of Grubb & Ellis Realty Advisors, Inc. (GAV:AMEX). The company is a development stage company formed to acquire commercial real estate properties. Mr. Lazar holds a Bachelor of Business Administration degree from The City College of New York (Baruch College).



SHAHRAM K. RABBANI Director, is a founder and was employed with the company until 2009. Mr. Rabbani is a former President of Enzo Clinical Labs and a past board member of on the New York State Clinical Laboratory Association, he received a Bachelor of Arts Degree in Chemistry from Adelphi University.

STEPHEN B. H. KENT Ph D., has been a Director of the Company since January 2007. Dr. Kent is or has been a Professor of Biochemistry & Molecular Biology (2001-present), Professor of Chemistry (2002-present), and Director of the Institute for Biophysical Dynamics (2003-present) at the University of Chicago. Dr. Kent was the business founder and served as a director of Ciphergen Biosystems (1994-1997) and Gryphon Sciences (1994-2002). At Gryphon Sciences, Kent served as President (1997-2000), CEO (1999-2000), and Chief Scientist (1997-2001). Dr. Kent has served on the Scientific Advisory Board at Amylin Pharmaceuticals from 2005 – present, the Board of the Center for Functional Genomics, Victoria University, New Zealand from 2004 – present, the Scientific Advisory Board, Institute for Molecular Bioscience, The University of Queensland, Australia, from 2001– present, and the Scientific Advisory Board, New York Blood Center & Kimball Research Institute from 1991–1997. Dr. Kent received B.Sc. and M.Sc. degrees in his native New Zealand, and his Ph.D. from the University of California, Berkeley.

Dr. Elazar Rabbani and Shahram K. Rabbani are brothers and Barry W. Weiner is their brother-in-law. John J. Delucca, John B. Sias, Irwin C. Gerson, Melvin F. Lazar and Dr. Stephen Kent qualify as “independent directors” under the criteria established by the New York Stock Exchange (“NYSE”).